Advanced Search

 

Study ID Status Title Patient Level Data
29060/595 Completed A Study of the Maintained Efficacy and Safety of Paroxetine versus Placebo in the Long-Term Treatment of Social Phobia
29060/621 Completed A randomized, double-blind, placebo-controlled trial of intermittent treatment with paroxetine 10mg/day and 20mg/day versus placebo in Canadian women with Premenstrual Dysphoric Disorder
29060/622 Completed Open study to evaluate the efficacy and safety of paroxetine in the treatment of minor depression.
29060/625 Completed A double-blind, placebo-controlled multi-centre study to evaluate the efficacy and tolerability of Paroxetine in the treatment of post-stroke depression. Study Listed on ClinicalStudyDataRequest.com
29060/627 Completed A 12-Week, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Efficacy and Tolerability of Paroxetine in Patients Suffering from Post-traumatic Stress Disorder (PTSD) Study Listed on ClinicalStudyDataRequest.com
29060/637 Completed A double-blind, placebo controlled study to evaluate the efficacy and tolerability of paroxetine in patients with Generalised Anxiety Disorder (GAD) Study Listed on ClinicalStudyDataRequest.com
29060/641 Completed A Randomized, Double-Blind, Placebo Controlled, Fixed Dosage Trial to Evaluate the Efficacy and Tolerability of 20 and 40mg/day Paroxetine in Patients with Generalized Anxiety Disorder Study Listed on ClinicalStudyDataRequest.com
29060/642 Completed A Randomized, Double-Blind, Placebo Controlled, Flexible Dosage Trial to Evaluate the Efficacy and Tolerability of Paroxetine in Patients with Generalized Anxiety Disorder Study Listed on ClinicalStudyDataRequest.com
29060/645 Completed A single-dose, group sequential, four period crossover study to demonstrate bioequivalence between 50 mg and two 25 mg controlled release paroxetine tablets manufactured at Cidra
29060/646 Completed A Study of the Maintained Efficacy and Safety of Paroxetine in Patients with Generalized Anxiety Disorder (GAD)
29060/648 Completed A 12 Week, Double-blind, Placebo-controlled, parallel group study to assess the efficacy and tolerability of Paroxetine in Patients suffering from Post-traumatic Stress Disorder (PTSD) Study Listed on ClinicalStudyDataRequest.com
29060/650 Completed A Study of the Maintained Efficacy and Safety of Paroxetine Versus Placebo in the Long-Term Treatment of Posttraumatic Stress Disorder Study Listed on ClinicalStudyDataRequest.com
29060/651 Completed A 12 week, double-blind, fixed dose comparison of 20 and 40 mg daily of paroxetine and placebo in Patients suffering from Post-traumatic Stress Disorder (PTSD). Study Listed on ClinicalStudyDataRequest.com
29060/653 Completed A single dose four-period crossover study to investigate the relative bioavailability of the new paroxetine dispersible tablet (20 mg) compared with a standard paroxetine 20 mg tablet Study Listed on ClinicalStudyDataRequest.com
29060/658 Completed A Placebo-Controlled Study to Investigate the Efficacy of Intermittent and Continuous Treatment With Paroxetine in Patients With Premenstrual Dysphoric Disorder (PMDD)
29060/661 Completed Clinical Evaluation of BRL29060A (Paroxetine Hydrochloride Hydrate) in Social Phobia/Social Anxiety Disorder (SAD) A Double-blind, Placebo-controlled Study
29060/663 Completed A single dose two-period cross-over study to demonstrate bioequivalence between a new paroxetine tablet (40 mg) and the standard Paxil tablet (40 mg)
29060/664 Completed A single dose randomised three-period cross-over study to evaluate the effect of food on the bioavailability of a new 40 mg paroxetine tablet when administered in the fed and fasted state relative to the bioavailability of the standard 40 mg Paxil™ tablet administered in the fed state.
29060/665 Completed A Phase I Pharmacokinetic and Pharmacodynamic Study on the Potential Drug-Drug Interactions between Paroxetine and Alprazolam
29060/676 Completed A 16 Week Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Tolerability of Paroxetine in the Treatment of Children and Adolescents with Social Anxiety Disorder/Social Phobia. Study Listed on ClinicalStudyDataRequest.com
29060/677 Completed A Double-Blind, Placebo-Controlled, Three-Arm Fixed-Dose Study of Paroxetine CR Continuous Treatment (12.5 mg/day and 25 mg/day) for Premenstrual Dysphoric Disorder Study Listed on ClinicalStudyDataRequest.com
29060/681 Completed Open study to evaluate the efficacy and the safety of paroxetine in the treatment of depression associated with a physical disorders
29060/688 Completed A double-blind, placebo-controlled, 3-arm fixed dose study of paroxetine CR continuous treatment (12.5mg and 25mg) for Premenstrual Dysphoric Disorder. Study Listed on ClinicalStudyDataRequest.com
29060/689 Completed A Double-Blind, Placebo-Controlled, 3-Arm, Fixed-Dose Study of Paroxetine CR Continuous Treatment (12.5 mg/day and 25 mg/day) for Premenstrual Dysphoric Disorder Study Listed on ClinicalStudyDataRequest.com
29060/701 Completed A multi-center, double blind, placebo-controlled flexible dose study to evaluate the efficacy and safety of Paroxetine in children with major depression. Study Listed on ClinicalStudyDataRequest.com

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.